Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas — ANGIO-TAX+  

Angiosarcoma Clinical Trial

Official title: Phase II Study, Multicenter, Randomized, Stratified, Evaluating the Efficacity of Weekly Paclitaxel, With or Without Bevacizumab in the Treatment of Metastatic or Locally Advanced Angiosarcomas Not Accessible to Surgery Treatment.

Status Completed

Clinical Trial Summary

Efficacity of Paclitaxel in association or not with Bevacizumab in treatment of angiosarcoma

Clinical Trial Description

Randomization is stratified :

• angiosarcoma in irradiated region : yes / no

• visceral angiosarcoma : yes / no

All patient will received a maximum of 6 cycles of weekly Paclitaxel (Arm A and B) in association or not with Bevacizumab (ArmB).

1 cycle = 28 days Treatment by Bevacizumab is to continue beyond the 6th cycle, until disease progression or unacceptable toxicity

Arm A and B:

Day 1, D8 and D15 Paclitaxel : 90 mg/m², IV weekly with premedication

Arm B :

Day 1 and D15 Bevacizumab : 10 mg/kg and then, Bevacizumab : 15 mg/kg/3 weeks until disease progression or unacceptable toxicity ;

Related Conditions & MeSH terms

• Angiosarcoma

• NCT number: NCT01303497
• Study type: Interventional
• Source: Centre Oscar Lambret
• Status: Completed
• Phase: Phase 2
• Start date: September 10, 2010
• Completion date: January 29, 2019